Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q3 2022 Results Conference Call August 4, 2022 5:00 PM ET
Company Participants
Vince Anzalone - VP, IR
Christopher Anzalone - President and CEO
Javier San Martin - Chief Medical Officer
Ken Myszkowski - CFO
James Hamilton - SVP, Discovery and Translational Medicine
Tracie Oliver - Chief Commercial Officer
Patrick O'Brien - Chief Operating Officer & General Counsel
Conference Call Participants
Luca Issi - RBC
Ted Tenthoff - Piper Sandler
Ellie Merle - UBS
Joel Beatty - Baird
Madhu Kumar - Goldman Sachs
Patrick Trucchio - HC Wainwright
Keay Nakae - Chardan
Mani Foroohar - SVB Securities
Mayank Mamtani - B. Riley FBR
Prakhar Agarwal - Cantor
Operator
Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions.
I will now hand the conference over to Vince Anzalone, Vice President of Finance and Investor Relations for Arrowhead. Please go ahead, Vince.
Vince Anzalone
Good afternoon, everyone. Thank you for joining us today to discuss Arrowhead's results for its Fiscal 2022 Third Quarter ended June 30, 2022.
With us today from management are President and CEO, Dr. Christopher Anzalone, who will provide an overview of the quarter; Dr. Javier San Martin, our Chief Medical Officer, who will provide an update on our mid-and later stage clinical pipeline. Dr. James Hamilton, our Senior Vice President of Discovery and Translational Medicine will provide an update on our earlier stage program and Ken Myszkowski, our Chief Financial Officer, will give a review of the financials. In addition, Tracie Oliver our newly appointed Chief Commercial Officer and Patrick O'Brien, who is recently promoted to Chief Operating Officer and General Counsel, will both be available during the Q&A portion of the call.
Before we begin, I would like to remind you that comments made during today's call contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking statements and are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. For further details concerning these risks and uncertainties, please refer to our SEC filings, including our most recent annual report on Form 10-K and our quarterly reports on Form 10-Q.